Key Takeaways
- • Goldman Sachs Alternatives has agreed to acquire a controlling stake in Numantec, an Italian medical technology manufacturer, from private equity firm White Bridge Investment, with the deal valued at approximately €700 million.
- • Numantec operates seven manufacturing facilities across Europe and the US, employs around 600 people, and manufactures medical devices and drug-delivery products from its headquarters near Mantua in northern Italy.
- • White Bridge built Numantec through a buy-and-build strategy beginning with its 2021 acquisition of Delta Med, followed by subsequent acquisitions including Health Line International's US operations acquired in 2025.
- • The transaction is expected to close in the fourth quarter of 2026, with Numantec anticipated to pursue continued growth opportunities across Europe while strengthening its US market position under Goldman Sachs Alternatives' ownership.
- • JPMorgan advised White Bridge on the sale, while Goldman Sachs International served as adviser to Goldman Sachs Alternatives.
Summary
Goldman Sachs Alternatives has secured a controlling stake in Numantec, an Italian medical technology platform, in a deal valued at approximately €700 million. The acquisition represents another significant healthcare sector investment by Goldman Sachs' alternatives arm and marks a transition of ownership from private equity firm White Bridge Investment, which has held the company through an active build-and-grow strategy over the past five years.
Numantec, headquartered near Mantua in northern Italy, is a diversified medtech manufacturer with substantial operational scale. The company operates seven manufacturing facilities spanning Europe and North America, employs approximately 600 people, and specializes in medical devices and drug-delivery systems. This operational footprint positions the company across key regulated markets, providing a foundation for continued expansion.
White Bridge constructed Numantec as a consolidated platform beginning in 2021 with its acquisition of Delta Med, a specialized vascular access device manufacturer. The firm subsequently expanded the platform through targeted acquisitions, most recently acquiring US-based Health Line International in 2025 to establish a meaningful North American presence. Goldman Sachs Alternatives' acquisition represents an exit opportunity for White Bridge while providing the medtech company with alternative capital and resources aligned with longer-term growth objectives.
Following completion, expected in the fourth quarter of 2026, Numantec is positioned to pursue organic and inorganic growth opportunities throughout Europe while consolidating and expanding its nascent US operations. The transaction was advised by JPMorgan on behalf of White Bridge, with Goldman Sachs International representing Goldman Sachs Alternatives throughout the negotiation process.
Numantec, headquartered near Mantua in northern Italy, is a diversified medtech manufacturer with substantial operational scale. The company operates seven manufacturing facilities spanning Europe and North America, employs approximately 600 people, and specializes in medical devices and drug-delivery systems. This operational footprint positions the company across key regulated markets, providing a foundation for continued expansion.
White Bridge constructed Numantec as a consolidated platform beginning in 2021 with its acquisition of Delta Med, a specialized vascular access device manufacturer. The firm subsequently expanded the platform through targeted acquisitions, most recently acquiring US-based Health Line International in 2025 to establish a meaningful North American presence. Goldman Sachs Alternatives' acquisition represents an exit opportunity for White Bridge while providing the medtech company with alternative capital and resources aligned with longer-term growth objectives.
Following completion, expected in the fourth quarter of 2026, Numantec is positioned to pursue organic and inorganic growth opportunities throughout Europe while consolidating and expanding its nascent US operations. The transaction was advised by JPMorgan on behalf of White Bridge, with Goldman Sachs International representing Goldman Sachs Alternatives throughout the negotiation process.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.